SEC Form 4 · accession 0001437749-26-022665
Nuo Therapeutics, Inc. · AURX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Emerson Jorden
Officer — CEO/CFO · Director
Period of report
Jun 29, 2026
Accepted (ET)
Jul 2, 2026 · 9:02 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001091596
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 30, 2026 | M | 162,500 | $1.00 | A | 2,222,119 | D | |
| Common StockF2 | Jun 30, 2026 | F | 160,892 | $1.01 | D | 2,061,227 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to purchase common stockF3 | $1.00 | Jun 30, 2026 | M | 162,500 | D | Dec 31, 2017 | Jun 30, 2026 | Common Stock | 162,500 | 0 | D |
| Option to purchase common stockF4 | $1.01 | Jun 29, 2026 | A | 125,000 | A | — | Jun 29, 2036 | Common Stock | 125,000 | 125,000 | D |
Explanation of responses
- F1Represents a net exercise of outstanding stock options. The reporting person received 1,608 shares of common stock on the net exercise of option to purchase 162,500 shares of common stock. The issuer withheld 160,892 shares of common stock underlying the option for payment of the exercise price using the closing price of $1.01.
- F2Reflects an adjustment of 25,381 shares since the Reporting Person's most recent Form 4 filed June 5, 2026 to correct the amount of securities beneficially owned as a result of the transaction reported in that Form 4.
- F362,500 options exercisable on 07/01/2016, 50,000 options exercisable on 03/31/2017, and 50,000 options exercisable on 12/31/2017.
- F4One third of the options are exercisable as of June 30, 2027 and the balance vest quarterly over the subsequent two years.